A clinic intake coordinator fields the same question three times in one afternoon: a patient has read a press release about a new obesity drug that beat tirzepatide, and wants to know if it's worth waiting for. The honest answer is more complicated than either the headline or the sales copy suggests. CagriSema and tirzepatide have never been randomized against each other in a completed trial. What exists instead is two separate trial programs — REDEFINE for CagriSema, SURMOUNT for tirzepatide — each measured against placebo, in different populations, under different statistical rules. Understanding what the CagriSema vs tirzepatide data actually supports, and where it runs out, matters more than repeating a percentage from a press release.
Why the Comparison Keeps Coming Up
Novo Nordisk's REDEFINE-1 topline results, released in December 2024, reported weight loss in the 20-23% range for CagriSema at 68 weeks. That number sits close enough to tirzepatide's 20.9% result in SURMOUNT-1 that comparison was inevitable, especially with Eli Lilly and Novo Nordisk competing directly for the obesity-treatment market. Financial analysts, clinicians fielding patient questions, and research-focused publications all reached for the same shorthand: has CagriSema caught up to, or surpassed, tirzepatide.
The comparison is reasonable to ask and premature to answer. REDEFINE-1 enrolled adults with obesity or overweight without type 2 diabetes; SURMOUNT-1 enrolled a similar but not identical population. Neither trial randomized participants to receive the competitor's drug. Cross-trial comparisons of this kind are common in pharma communications and useful for generating hypotheses, but they are not equivalent to head-to-head randomized evidence, and regulatory bodies do not treat them as such when evaluating comparative efficacy claims.
For a broader look at how tirzepatide's own head-to-head data against semaglutide was generated, see the SURMOUNT-5 head-to-head trial analysis, which shows what a genuine randomized comparison looks like in this drug class and why it differs structurally from the CagriSema-tirzepatide comparison being drawn today.
Mechanism: Dual Amylin-GLP-1 vs Dual GIP-GLP-1
CagriSema is a co-formulation of two separate peptides: cagrilintide, a long-acting amylin receptor agonist, and semaglutide, the GLP-1 receptor agonist already marketed as Ozempic and Wegovy. Amylin is co-secreted with insulin from pancreatic beta cells and acts on amylin receptors in the area postrema and nucleus tractus solitarius to slow gastric emptying and promote satiety through a pathway distinct from, but complementary to, GLP-1 signaling. Pairing the two is intended to produce appetite suppression through two independent central nervous system circuits rather than one.
Tirzepatide takes a different structural approach: it is a single 39-amino-acid peptide engineered to activate both the GIP receptor and the GLP-1 receptor, with greater relative potency at the GIP receptor in preclinical binding assays. The GIP component's contribution to weight loss in humans is still debated in the literature, but the dual-agonism design is credited with tirzepatide's larger effect size relative to GLP-1-only agonists in cross-trial comparisons.
The mechanistic distinction matters clinically because it predicts where tolerability differences might emerge. Amylin agonism has a documented association with nausea and delayed gastric emptying similar to GLP-1 agonism, meaning CagriSema's two components may have overlapping rather than offsetting GI effects. A deeper explanation of the gastric-emptying pathway shared across this drug class is available in this mechanism review of GLP-1 receptor agonists and gastric emptying, and the broader receptor pharmacology is covered in this GLP-1 receptor mechanism of action summary.
REDEFINE-1: Trial Design and Topline Weight-Loss Data
REDEFINE-1 (NCT05567418) randomized adults with obesity or overweight and at least one weight-related comorbidity, excluding type 2 diabetes, to CagriSema or placebo over 68 weeks, with dose escalation to a target maintenance dose of 2.4 mg cagrilintide / 2.4 mg semaglutide weekly. Topline results reported a mean weight reduction of approximately 22.7% under the trial product estimand — reflecting outcomes among participants who remained on treatment — and approximately 20.4% under the treatment policy estimand, which includes participants regardless of adherence. The placebo arm lost approximately 2.3% under the same treatment policy estimand.
Roughly 40% of participants in some reported subgroups reached 25% or greater weight loss, a threshold not commonly reached with single-mechanism GLP-1 agonists in prior trials. These figures, however, come from a company press release and investor communication rather than a peer-reviewed manuscript at the time of writing, so effect sizes, confidence intervals, and full adverse-event tables should be treated as provisional until publication permits independent verification.
Discontinuation due to adverse events was reported in the mid-single-digit percentage range, consistent with rates seen in other injectable incretin-based trials. Full secondary endpoint data — waist circumference, blood pressure, lipid panels — were not detailed in the initial release, which is a meaningful gap for clinicians assessing metabolic benefit beyond the scale.
REDEFINE-2: Data in Type 2 Diabetes
REDEFINE-2 (NCT05869929) enrolled adults with type 2 diabetes and overweight or obesity, a population that historically shows attenuated weight-loss response to incretin therapies relative to those without diabetes — a pattern already well documented for semaglutide and tirzepatide. Reported results placed CagriSema's weight-loss effect in the type 2 diabetes population meaningfully lower than in REDEFINE-1, in the range of roughly 13-16% depending on estimand, though again from topline reporting rather than a completed peer-reviewed dataset.
This attenuation mirrors the tirzepatide experience: SURMOUNT-1 (without diabetes) reported 20.9% weight loss at the 15 mg dose, while SURMOUNT-2 (with type 2 diabetes) reported approximately 14.7% at the same dose over the same 72-week duration. The consistency of this pattern across both drug programs suggests the attenuation is more likely attributable to underlying diabetes pathophysiology — altered insulin dynamics, longer disease duration, comorbid medication use — than to a mechanism-specific weakness in either compound.
REDEFINE-2 also included an active semaglutide comparator arm in some reporting, which is closer to genuine head-to-head evidence than anything available against tirzepatide. Clinicians and researchers tracking cardiometabolic outcomes in this population may find it useful to cross-reference the SELECT trial four-year cardiovascular outcomes review, since long-term cardiovascular data will likely become a differentiating factor between these drug classes well before head-to-head efficacy trials are completed.
SURMOUNT-1 and SURMOUNT-2: The Tirzepatide Comparator Data
SURMOUNT-1, published in the New England Journal of Medicine (Jastreboff et al., PMID 35658024), randomized 2,539 adults with obesity or overweight without type 2 diabetes to tirzepatide 5 mg, 10 mg, 15 mg, or placebo over 72 weeks. The 15 mg group achieved a mean weight reduction of 20.9%, compared with 3.1% for placebo, with 63% of participants on the highest dose achieving at least 20% weight loss. This remains one of the most robust, fully peer-reviewed efficacy datasets in the obesity pharmacotherapy literature.
SURMOUNT-2, published in The Lancet (Garvey et al., PMID 37385275), enrolled 938 adults with type 2 diabetes and obesity or overweight. The 15 mg tirzepatide group achieved 14.7% mean weight loss at 72 weeks versus 3.3% for placebo — a smaller absolute effect than SURMOUNT-1, consistent with the diabetes-attenuation pattern also observed in the REDEFINE program.
Both SURMOUNT trials benefit from full publication, independent peer review, and detailed adverse-event and subgroup reporting that the REDEFINE press releases do not yet match. That publication gap is not a mechanistic weakness of CagriSema — it is a timing and evidentiary maturity difference that should factor into how confidently any comparison is stated. Detailed dosing protocols for the GLP-1 side of this comparison are covered in this semaglutide dose titration schedule review.
Cross-Trial Comparison: What the Numbers Suggest and What They Don't
Laid side by side, the topline numbers are close: roughly 20.4% (CagriSema, treatment policy, 68 weeks) versus 20.9% (tirzepatide 15 mg, 72 weeks). A four-week difference in trial duration, different weight-loss trajectories that had not necessarily plateaued in either trial, and different estimand conventions make even this narrow gap difficult to interpret as a meaningful efficacy difference in either direction.
Baseline population characteristics also diverge. Differences in mean baseline BMI, sex distribution, race and ethnicity representation, and background comorbidity rates between REDEFINE-1 and SURMOUNT-1 cohorts can shift observed effect sizes independent of the drug itself. None of the published or released materials to date include a formal statistical test comparing the two arms across trials, because such a test would not be methodologically valid without individual patient-level data and a pre-specified cross-trial analysis plan.
What can be said with reasonable confidence: both approaches — dual amylin/GLP-1 agonism and dual GIP/GLP-1 agonism — outperform single-mechanism GLP-1 agonism alone by a wide margin in their respective trial populations. Semaglutide alone, in the STEP program, produced approximately 14.9% weight loss at 68 weeks in comparable populations, meaningfully below both CagriSema and tirzepatide. The dual-mechanism strategy itself appears more consequential than which specific second receptor is targeted, though that remains a hypothesis pending head-to-head confirmation.
Safety and Tolerability Profiles Side by Side
Gastrointestinal adverse events dominate the safety profile of both drugs. In SURMOUNT-1, nausea occurred in approximately 31% of the 15 mg tirzepatide group versus 10% on placebo, diarrhea in approximately 23% versus 10%, and vomiting in approximately 12% versus 2%. These events clustered during dose-escalation phases and generally declined in frequency at steady-state maintenance dosing.
CagriSema's reported adverse-event profile in early releases follows a similar pattern — nausea, vomiting, constipation, and diarrhea as the leading complaints — though granular percentage breakdowns by symptom have not been fully disclosed outside abstract-level reporting at the time of writing. Given that cagrilintide alone has shown a nausea signal in earlier-phase trials, and semaglutide's GI profile is well established from the STEP program, there is no mechanistic reason to expect CagriSema's combined GI burden to be substantially lower than tirzepatide's, though it has not been formally compared.
Neither drug's released data to date have flagged pancreatitis, gallbladder disease, or thyroid C-cell tumor signals at rates statistically distinguishable from their respective placebo arms, but sample sizes in individual trials remain underpowered to detect rare events. Longer-term registry and post-marketing surveillance data, once available, will carry more weight for rare-event assessment than trial-level adverse-event tables. Muscle mass preservation during rapid weight loss is a related monitoring consideration for both drug classes, discussed in this review of GLP-1 therapy and lean muscle mass.
Dosing, Titration, and Administration Differences
Tirzepatide is administered as a once-weekly subcutaneous injection, titrated from a 2.5 mg starting dose in 2.5 mg increments approximately every four weeks, up to a maximum studied dose of 15 mg. This stepwise schedule was designed specifically to mitigate GI tolerability issues, and published titration protocols document exactly how discontinuation rates track with escalation pace.
CagriSema's studied regimen also follows a once-weekly subcutaneous schedule, escalating toward a maintenance dose of 2.4 mg cagrilintide combined with 2.4 mg semaglutide, mirroring the semaglutide titration ceiling used in the STEP and SELECT programs. Because cagrilintide and semaglutide are co-formulated in a single pen in the trial design, patients are not titrating two separate injections, which may simplify adherence relative to a hypothetical unbundled regimen, though this has not been formally tested as an adherence variable.
Neither drug currently has an FDA-approved label; tirzepatide's approved dosing under Mounjaro and Zepbound reflects the SURMOUNT and SURPASS program's approved ranges, while CagriSema's eventual label, if approved, will depend on the final REDEFINE dataset submitted to regulators. Clinicians managing patients on approved tirzepatide products in the interim should reference official prescribing information rather than trial-phase dosing tables, since post-approval labeling can differ from the exact schedules used in registration trials.
What Remains Unknown
The single largest gap is the absence of a randomized, adequately powered head-to-head trial between CagriSema and tirzepatide. Without one, statements that either drug is "more effective" than the other are not supportable by the current evidence base, regardless of how similar or different the topline percentages appear. [CITATION NEEDED: any registered head-to-head CagriSema vs. tirzepatide randomized trial, if initiated after this data was compiled.]
Cardiovascular outcomes data comparable to the SELECT trial's four-year tirzepatide-class follow-up do not yet exist for CagriSema. Long-term durability of weight loss beyond 68-72 weeks, discontinuation-related weight regain patterns, and effects on lean mass preservation are also less mature for CagriSema than for tirzepatide, where longer maintenance-dosing data are beginning to accumulate. The discontinuation and regain literature for this drug class more broadly is summarized in the STEP 4 long-term follow-up findings on discontinuation and weight regain and in the SURMOUNT-4 withdrawal and regain analysis, both relevant to how either drug might behave once maintenance dosing ends.
Full peer-reviewed publication of REDEFINE-1 and REDEFINE-2 — with complete methods, adjudicated adverse events, and subgroup analyses — will materially change how confidently any comparison can be drawn. Until that publication occurs, topline press-release figures should be treated as provisional.
Clinical Decision-Making Considerations
For a prescriber weighing options today, the practical reality is that tirzepatide is FDA-approved, has a fully published pivotal trial dataset, and has accumulating real-world and cardiovascular outcomes data, while CagriSema remains investigational with topline-only results. That regulatory and evidentiary status — not the raw percentage difference in reported weight loss — is the more clinically decisive fact in the near term.
When CagriSema's full dataset is published and, if approved, becomes clinically available, the decision-relevant variables will likely include comparative GI tolerability at matched titration speeds, effect in patients with type 2 diabetes specifically, cardiovascular and renal outcome data comparable to what exists for tirzepatide via the SELECT and FLOW trials, and injection-device or administration preferences. Renal outcome considerations already documented for GLP-1 receptor agonists are covered in the FLOW trial kidney endpoint analysis, which represents the kind of outcome dataset CagriSema will eventually need before a full comparative clinical picture is possible.
The most defensible position for both clinicians and informed patients at this stage is to treat CagriSema and tirzepatide as two distinct, independently promising approaches whose relative efficacy and safety cannot yet be ranked. Tracking the peer-reviewed publication of REDEFINE-1 and REDEFINE-2, and watching for any registered head-to-head trial, is the concrete next step for anyone trying to move past press-release percentages toward decision-grade evidence.
This article summarizes research and does not constitute medical advice. Consult a licensed clinician for diagnosis, treatment, or any decisions about medications or supplements.